Although ADAM17's expression is downregulated in physiological states, several studies have demonstrated its upregulation along with its substrates [tumor necrosis factor-alpha (TNFα) and soluble interleukin-6 receptor (sIL-6R)] in dilated cardiomyopathies (16–19). Here, IL6R is linked to dilated cardiomyopathy.